These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9057740)

  • 41. Problems with interpreting the data in Kassler-Taub et al's article comparing irbesartan and losartan.
    Bunt T
    Am J Hypertens; 1999 Jan; 12(1 Pt 1):79-81. PubMed ID: 10075390
    [No Abstract]   [Full Text] [Related]  

  • 42. A new class of antihypertensive therapy: angiotensin II receptor antagonists.
    Ellis ML; Patterson JH
    Pharmacotherapy; 1996; 16(5):849-60. PubMed ID: 8888079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A risk-benefit assessment of losartan potassium in the treatment of hypertension.
    Burrell LM
    Drug Saf; 1997 Jan; 16(1):56-65. PubMed ID: 9010643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Angiotensin receptor antagonists. A new class of antihypertensive agents].
    Mann J
    Dtsch Med Wochenschr; 1996 Apr; 121(17):568-71. PubMed ID: 8620827
    [No Abstract]   [Full Text] [Related]  

  • 46. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Angiotensin II antagonists].
    Tikkanen I; Tikkanen T
    Duodecim; 1995; 111(18):1733-5. PubMed ID: 9340266
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of chronic losartan potassium treatment on fructose-induced hypertension.
    Iyer SN; Katovich MJ
    Life Sci; 1994; 55(7):PL139-44. PubMed ID: 8041226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of pulsed-wave Doppler echocardiography to measure changes in MPAP. Is further validation required?
    Morrell NW
    Chest; 1997 May; 111(5):1469-70. PubMed ID: 9149625
    [No Abstract]   [Full Text] [Related]  

  • 50. New angiotensin-II blocker.
    Lilley LL; Guanci R
    Am J Nurs; 1996 Mar; 96(3):20. PubMed ID: 8607540
    [No Abstract]   [Full Text] [Related]  

  • 51. Angiotensin II receptor antagonists: the prototype losartan.
    Schaefer KL; Porter JA
    Ann Pharmacother; 1996 Jun; 30(6):625-36. PubMed ID: 8792950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan.
    Bunt T
    Clin Ther; 1999 Mar; 21(3):611-2. PubMed ID: 10321426
    [No Abstract]   [Full Text] [Related]  

  • 53. Cardiology patient page. Angiotensin receptor blockers.
    Terra SG
    Circulation; 2003 Jun; 107(24):e215-6. PubMed ID: 12821593
    [No Abstract]   [Full Text] [Related]  

  • 54. Angiotensin II receptor antagonists, elite drugs (or not) for patients with heart failure or hypertension?
    Beevers DG; Lip GY
    J Hum Hypertens; 1997 Jun; 11(6):329-30. PubMed ID: 9249225
    [No Abstract]   [Full Text] [Related]  

  • 55. Angioedema of the intestine.
    Gabb GM
    N Engl J Med; 1996 Nov; 335(20):1534-5; author reply 1535. PubMed ID: 8927095
    [No Abstract]   [Full Text] [Related]  

  • 56. Losartan versus captopril in elderly patients with heart failure.
    Sechi LA; Catena C; Bartoli E
    Lancet; 1997 May; 349(9063):1474; author reply 1475. PubMed ID: 9164337
    [No Abstract]   [Full Text] [Related]  

  • 57. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study.
    Nielsen S; Dollerup J; Nielsen B; Jensen HA; Mogensen CE
    Nephrol Dial Transplant; 1997; 12 Suppl 2():19-23. PubMed ID: 9269694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension.
    Himmelmann A; Svensson A; Bergbrant A; Hansson L
    J Hum Hypertens; 1996 Nov; 10(11):729-34. PubMed ID: 9004102
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension.
    Grossman E; Peleg E; Carroll J; Shamiss A; Rosenthal T
    Am J Hypertens; 1994 Dec; 7(12):1041-4. PubMed ID: 7702796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiproteinuric effect of Losartan in patients with chronic renal diseases.
    Zoccali C; Valvo E; Russo D; Panichi V; Zuccala' A
    Nephrol Dial Transplant; 1997 Jan; 12(1):234-5. PubMed ID: 9027813
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.